Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
microbiome
Biotech
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Vedanta is reorienting resources toward lead candidate VE303, which is chasing the tail of Seres’ Vowst in treating recurrent C. diff infections.
Darren Incorvaia
Aug 13, 2025 1:48pm
Fecal transplants alleviate fibromyalgia pain in small trial
Apr 28, 2025 7:30am
Vaccine-probiotic combo clears gut infections in mice
Apr 9, 2025 5:25am
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing
Jan 9, 2025 5:18am
Xeno's gastric-bypass pill alternative to be tested for C. diff
Jan 6, 2025 7:15am
Compounds from vaginal bacteria show promise for inflammation
Oct 17, 2024 11:00am